A Safety and Effective Study of Ginkgolides Diterpene Lactone Meglumine Injection in the Treatment of Ischemic Stroke.
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 3452 participants.
Also called NCT02526225
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 3,452 participants
- Sponsor
- Registry
-
NCT02526225
-
- Other papers using this trial's data
- Effect of ginkgo diterpene lactone meglumine on the quality of life in patients with acute ischemic stroke
- Efficacy and Safety of Ginkgo Diterpene Lactone Meglumine in Acute Ischemic Stroke: A Randomized Clinical Trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT02526225. Randomized; triple masking; primary purpose treatment. Start 2016-02-01 (registry gives no type); primary completion 2018-05-01 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Safety and Effective Study of Ginkgolides Diterpene Lactone Meglumine Injection in the Treatment of Ischemic Stroke.
- Condition
- Ischemic Stroke
- Intervention (Drug)
- Ginkgo diterpene lactone meglumine injection
- Intervention (Drug)
- Ginkgo diterpene lactone meglumine injection simulation
- Lead sponsor
- Beijing Tiantan Hospital
- Collaborator
- Beijing Bionovo Medicine Development Co., Ltd.
Record details
- Record id
cardio:ct-nct02526225- Content hash
2f8e84aa4d51415787b10b4986b73dcced51590698b87f9be6ecc2c548cd63e8